Reckitt Benckiser Group Plc maintained its 2026 revenue growth targets after strong performance in emerging markets boosted sales last year. The UK-based consumer goods company, known for Dettol and Harpic, expects its core brands to grow 4% to 5% by 2026 despite weaker cold and flu product demand in early 2025. Revenue grew 5.2% in 2025, slightly above estimates.

CEO Kris Licht, now two-and-a-half years into his turnaround strategy, completed the $4.8 billion sale of Reckitt's home essentials division to Advent International last December. The company is also preparing to divest its infant formula business, Mead Johnson, once US lawsuits are resolved. Shares have risen 12% over the past year through Wednesday's close.

While US consumers cut spending on over-the-counter drugs amid a weak cold season, Licht said Reckitt's non-seasonal US business remains strong. The company has denied claims it hid risks about its premature-infant formula causing necrotizing enterocolitis. Mead Johnson recently avoided the global formula contamination crisis affecting rivals like Nestlé and Danone because it uses different ingredient suppliers.